脑转移瘤立体定向放疗剂量效应模型:SAFER研究前瞻初步数据
SAFER前瞻观察研究纳入91例未接受过放疗或神经外科手术、SRS后随访达9个月的脑转移瘤患者,采用LQC模型BED10进行剂量效应建模。9个月局部控制率为92.01%,LQC模型BED10与局部控制显著相关(OR 1.145,p=0.0132),BED10 45 Gy可实现>90%的9个月局部控制。
要点
- 9个月局部控制率92.01%,LQC模型BED10与局部控制显著相关(OR 1.145,p=0.0132)。
- LQC模型BED10 45 Gy可实现9个月局部控制>90%,等效单次SRS>20 Gy或3次SRS>27 Gy。
- BED10 35 Gy预测9个月局部控制71.50%,BED10 55 Gy增至97.4%。
核心结论
- LQC模型BED10 45 Gy是实现9个月局部控制>90%所需的剂量水平,等效单次SRS剂量>20 Gy或3次SRS剂量>27 Gy。
研究设计与样本
- 前瞻性观察研究SAFER(IRAS 276567)纳入91例无既往放疗或神经外科手术、SRS后随访达9个月的脑转移瘤患者。
主要发现
- 总体9个月局部控制率为92.01%。
- LQC模型BED10与局部控制显著相关(OR 1.145,斜率2.479,p=0.0132)。
- BED10 35 Gy者预测9个月局部控制率为71.50%,BED10 55 Gy者增至97.4%。
关键数值与推荐
- 基于回归模型,LQC模型BED10 45 Gy对应9个月局部控制>90%,等效单次SRS>20 Gy或3次SRS>27 Gy。
临床怎么用
- 处方剂量可参考LQC模型BED10≥45 Gy以实现9个月局部控制>90%,对应单次SRS>20 Gy或3次SRS>27 Gy。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The number of people living with brain metastases (BMs) has increased in the last decade. Despite the large number of patients treated with stereotactic radiosurgery (SRS), there are very few prospective studies of the dose-response relationship to guide practice. We present preliminary dose-response data from a prospective observational study of post-SRS outcomes in patients with BMs (SAFER, IRAS 276567). MATERIAL AND METHODS: The first 91 patients who did not have prior radiotherapy or neuro-surgery, to reach 9-months post-SRS follow up in the SAFER study were included. Local control (LC) probability was calculated using Kaplan Meier methodology. Prescription doses were converted to Biologically Effective Doses (BED) using the linear quadratic cubic (LQC) equation, and an alpha-beta ratio of 10. Logistic regression was used for dose-response modelling on a per-lesion basis. RESULTS: The overall 9-month LC rate was 92.01 %. The dose-response curve demonstrated a significant relationship between LQC model BED10 and LC (odds ratio 1.145, slope 2.479, p = 0.0132). Based on the regression model, 71.50 % of those receiving LQC model BED10 35 Gy were predicted to have LC at 9 months. This increased to 97.4 % in those receiving LQC model BED10 55 Gy. CONCLUSION: This is a large prospective dataset on the dose-response relationship of BMs treated with SRS. Our results indicate an LQC model BED10 45 Gy is required to achieve 9-month LC of > 90 %. This is equivalent to single fraction-SRS doses > 20 Gy, or 3-fraction SRS doses > 27 Gy.
引用
- de Boisanger J, Tran A, Benjamin P, et al. Dose-response modelling of stereotactic radiosurgery for brain metastases: Preliminary prospective data from the SAFER study (IRAS 276567). Radiother Oncol. 2025. PMID: 40812484. doi:10.1016/j.radonc.2025.111067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。